Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by fullhouse101on May 31, 2011 4:54pm
220 Views
Post# 18651801

keep a core.

keep a core.I expect one could keep a few of these in a long term account ( regardless of traders ). It will make you money in the future. 

The global confirmatory phase III clinical trial for KIACTATM was initiated on December 14, 2010. The trial is designed to confirm the safety and efficacy of KIACTATM in preventing renal function decline in patients diagnosed with AA amyloidosis. It will involve approximately 230 patients enrolled from approximately 72 sites in 30 countries worldwide. Enrolment has commenced and is estimated to be completed in mid-2012. The confirmatory phase III clinical trial is the last key step before applications for regulatory approval for KIACTATM can be filed. It is currently estimated that the trial will be completed in 2014.

Keep in mind, Celtic Therapeutics is assuming all costs related to the confirmatory phase III clinical trial and other development activities, estimated at an additional $25-million (U.S.). Celtic Therapeutics intends to conduct an auction process for the commercialization rights of Kiactaa upon completion of the confirmatory phase III clinical trial, the overall proceeds of which are expected to be shared equally between the parties.


And don't forget about NRM8499 prodrug Ccandidate

In January, 2011, Bellus Health completed the phase I clinical trial for NRM8499. Results of the trial showed a solid potential for pursuing NRM8499 for the treatment of Alzheimer's disease. The phase I clinical trial data demonstrated that NRM8499 was safe and well tolerated at the intended therapeutic dose. Moreover, the gastrointestinal tolerability and pharmacokinetic profile of tramiprosate, with regard to the interindividual variability in drug-systemic exposure, were meaningfully improved with NRM8499 when compared to the administration of an equivalent dose of tramiprosate. The company is currently seeking a potential partnership to pursue the development process of NRM8499.


Distribution/ accumulation of shares from you know who. But another 10% of their position might have off loaded today at a loss. Interesting they would sell here. Ink report showed 31 mil balance, from 56, but no activity for May. hmmm. Worth a look for TA guys NVI and PVI indicators.

FH
Bullboard Posts